EUCTR2012-001813-17-GB进行中（未招募）1 期
Study of apoptosis related changes and endothelial responses of multiple myeloma patients treated with chemotherapy. - procoagulant mechanisms of chemotherapy in multiple myeloma
Hull and East Yorkshire Hospitals NHS Trust0 个研究点目标入组 42 人开始时间: 2012年5月4日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 42
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •Patients who meet the following criteria are eligible for study entry:
- •Multiple myeloma groups:
- •1.Patients with a confirmed diagnosis of symptomatic multiple myeloma based on
- •the presence of a paraprotein in serum and/or urine organ damage (e.g osseous appearances) or symptoms considered by the clinician to be related to myeloma
- •2.Patients requiring treatment for their myeloma either at presentation or at the time of relapse
- •3.Aged 18 years or greater
- •4.Provide written informed consent
- •Myeloproliferative group (Non- Myeloma Control):
- •1.Patients with myeloproliferative disorders have a known propensity to develop thromboses (non treatment related) and will serve as the positive control group for this study. There are three major categories of myeloproliferative disorders: Chronic myelocytic leukemia, polycythemia rubra vera and myelofibrosis. These patients are followed up in a regular clinic in haematology outpatients. Based on the expected age and gender distribution of the experimental group ten of these control patients will be approached for consent in to the study. The same exclusion criteria (3.1.3) as for the experimental group will be adhered to.
- •2.Aged 18 years or greater
- •3.Provide written informed consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 100
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 10
排除标准
- •Patients with the following characteristics are ineligible for this trial:
- •1.Patients and participants suffering from any of the following conditions known to cause elevation of microparticles (except renal disease and chronic renal failure). These include; active infection, uncontrolled hypertension, diabetes mellitus with HBA1C indicative of poor diabetic control, recent myocardial infarction < 3 months, rheumatoid arthritis or other inflammatory process in active phase (e.g psoriasis).
研究者
相似试验
招募中
不适用
Molecular background of endothelial cell loss in patients with phakic intraocular lenses (MoBack-ECL): a tear and aqueous humour analysis studyEndothelial cell losssub-clinical inflammation10002693NL-OMON56417Medisch Universitair Ziekenhuis Maastricht126
已完成
2 期
A clinical trial to study the effect of phacoemulsification and manu small incision cataract surgery on endothelial cell changesCTRI/2019/11/022169King Georges Medical Univeristy152
已完成
不适用
Investigation of endothelial toxicity after allogeneic haematopoietic stem cell transplantatioACTRN12616000709448Fiona Stanley Hospital30
尚未招募
不适用
Changes in the front part of eye after cataract surgeryCTRI/2021/01/030314Aravind Eye Hospital Pondicherry
已完成
不适用
The Relation between Impairment of Endothelium-dependent Coronary Blood Flow Volume Change and Higher Platelet AggregabilityJPRN-UMIN000031390Kumamoto univercity hospital25